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Thrombin is a serine protease that plays fundamental roles in hemostasis. We have recently elucidated
the crystal structure of thrombin in complex with suramin, evidencing the interaction through the anion
binding exosite 2. Here, we show that the activity of thrombin toward natural and synthetic substrates is
enhanced by suramin as well as analogs of suramin at a lowmicromolar range prior to an inhibitory com-
ponent at higher concentrations. Suramin analogs substituted by phenyl and chlorine instead of methyl
were the most efﬁcient in promoting allosteric activation, with an enhancement of enzymatic activity of
250% and 630% respectively. We discuss the importance of exosite 2 as a regulatory site for ligands in
both the procoagulant and inhibitory scenarios.
 2012 Elsevier Inc. Open access under the Elsevier OA license. Introduction tions, a reﬂex of its correspondence between conformational diver-Alpha-thrombin is a serine protease that plays fundamental
roles in the coagulation and ﬁbrinolytic pathways and is therefore
an important target in drug design. Thrombin plays a central role in
the coagulation cascade in injuries and other conditions related to
hemostasis and system homeostasis. It mediates the conversion of
ﬁbrinogen to ﬁbrin and the activation of platelets and coagulation
factors V, VIII, XI, and XIII [1–5]. The precise control of coagulation
is inherently dependent on a ﬁne-tuned regulation of both the
procoagulant and the anticoagulant events. Thrombin has few sub-
strate requirements. In contrast, it can be modulated by a large
number of cofactors at distinguished physiopathological condi-methylketone; Suramin, 8,80-[car
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[carbonylbis[imino-3,1-phenylenec
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; S-2238, H–D-Phe-Pip-Arg-p-nitro
ima).
he Elsevier OA license. sity and activation-inhibition proﬁle [6–9].
Thrombin is composed of two disulﬁde-linked chains, L (‘‘light’’)
and H (‘‘heavy’’), with the catalytic site located in the H chain. The
understanding of the ligand recognition at the active site on a
molecular basis is key in the development of new compounds as
drug candidates targeting the coagulation process. The recognition
and binding of thrombin is mainly performed by two patches in the
thrombin surface, known as anion binding exosites 1 and 2. Exosite
1 is responsible for the recognition of ﬁbrin, ﬁbrinogen, protease-
activated receptor 1 (PAR-1) [10], and thrombomodulin, among
other ligands[11,12]. Exosite 2 is well known for its role as the hep-
arin-binding exosite.bonylbis[imino-3,1-phenylenecarbonylimino-3,1-(4-methylphenylene)carbonylimi-
mino-3,1-phenylenecarbonylimino-3,1-phenylenecarbonylimino]]bis[naphthalene-
arbonylimino-3,1-(4-ethylphenylene)carbonylimino]]bis[naphthalene-1,3,5-trisulf-
-3,1-(4-isopropylphenylene)carbonylimino]]bis[naphthalene-1,3,5-trisulfonic acid]
enylphenylene)carbonylimino]]bis[naphthalene-1,3,5-trisulfonic acid] hexasodium
e)carbonylimino]]bis[naphthalene-1,3,5-trisulfonic acid] hexasodium salt; NF258,
ino]]bis[naphthalene-1,3,5-trisulfonic acid] hexasodium salt; NF260, 8,80-[carbon-
is[naphthalene-1,3,5-trisulfonic acid] hexasodium salt; NF222, 8,80-[carbonyl-
o]]bis[naphthalene-1,3,5-trisulfonic acid] hexasodium salt; NF023, 8,80-
] hexasodium salt; MK012, 4,40-[carbonylbis[imino-3,1-phenylenecarbonylimi-
anilide; TBS, 20 mM Tris–HCl, 150 mM NaCl, pH 7.5.
Fig. 1. Suramin, suramin analogs and interaction with thrombin. (A) Chemical structure of suramin and suramin analogs. Compound nomenclatures are as stated in Table 1.
(B) Ribbon representation of the thrombin:suramin complex (PDB entry 2H9T; red for alpha-helices, yellow for beta-sheet) in superposition with free thrombin (PDB entry
1PPB; cyan for alpha-helices, magenta for beta-sheet), rotated 45 o in the X-axis from the standard orientation. (C) Details of the suramin interaction with the thrombin
exosite 2. Dotted lines represent water (red spheres) mediated contacts. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article).
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that has been frequently used in the treatment of African trypano-
somiasis and ﬁlariasis and has served as a lead compound in the
development of derivatives designed for the treatment of tropical
diseases, cancer, and hemostatic effects of snake venom, among
others [13–17].
Suramin was found to interact with thrombin through the anion
binding exosite 2, thus inhibiting the activity of thrombin toward
ﬁbrinogen and the synthetic substrate S-2238 [18,19]. Calorimetric
measurements suggested that the interaction occurred through at
least two separate events in a concentration-dependent mode [18].
In a previous study, we have shown that a thrombin:suramin di-
mer can exist in solution [19]. Molecular dynamic simulation
showed that while a dimer of the thrombin:suramin complex
(Fig. 1B) is conformationally stable compared to the crystal struc-
ture, the monomeric form of the thrombin:suramin complexundergoes deviations from the initial conformation in the crystal
matrix, as well as suramin, whose coordinates are affected except
for the naphthalenesulfonate moiety, which is responsible for
anchoring to the anion binding exosite 2 (Fig. 1C) [19].
Another important insight obtained from the thrombin:suramin
crystal structure is the presence of a shallow cavity close to one of
the suramin methyl groups [19]. This cavity is occupied by a water
molecule trapped within the interactions with the Gln244 side
chain, the phenolic hydroxyl from Tyr89, and the amidic carbonyl
from Val241 (Fig. 1C). These features create a polar environment in
this cavity, providing a repulsive interaction with the suramin
methyl group. Functionalization of suramin at this position would
allow modulation of the interaction potential with thrombin.
In the present work, we report the investigation of a series of
suramin analogs (Fig. 1A) and their effects on thrombin activity
against the natural substrate ﬁbrinogen. A dual effect over the
Fig. 2. Suramin exerts dual effects over ﬁbrinogen clotting by thrombin. Effects of
increasing concentrations of suramin in the activity of thrombin (1 nM) against
ﬁbrinogen (2 mg/mL) clotting. The ordinate is the relative enzymatic activity,
corresponding to the ratio between the initial rate of ﬁbrinogen clotting in the
presence/initial rate (in the absence of suramin). Data represent the mean ± S.D. of
three independent determinations performed in triplicate.
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component preceded by an activation phase. We discuss the allo-
steric nature of these phenomena in the light of a possible proco-
agulant regulatory function of the anion binding exosite 2.
Experimental procedures
Materials
Distilled water was deionized to less than 1.0 lS and ﬁltered
through a 0.22 lm pore-sized membrane with a water puriﬁcation
system prior to use. S-2238 was obtained from Chromogenix
(Mölndal, Sweden). Suramin was purchased from Sigma Chemical
(St. Louis, MO). Suramin analogs were synthesized as described
elsewhere [16]. Human ﬁbrinogen was purchased from Calbio-
chem (La Jolla, CA). Fluorescein-D-Phe-Pro-Arg-chloromethyl ke-
tone (PPACK) was from Hematologic Technologies Inc (Essex
Junction, VT). Human thrombin was puriﬁed as previously
described [20]. Protein concentrations were determined by UV
absorbance at 280 nm with an extinction coefﬁcient of
1.82 mg mL1 cm1 [21,22]. All other reagents were of analytical
grade. All buffers and solutions were prepared immediately prior
to use.
Assay for ﬁbrinogen clotting
Fibrinogen clotting was measured on a microplate reader
(Molecular Devices, Menlo Park, CA), as described elsewhere [23].
After a 5 min incubation of thrombin with suramin analogs at
37 C, the reaction was initiated by the addition of human ﬁbrino-
gen (4 mg/mL, ﬁnal concentration). The initial rate of ﬁbrinogen
clotting was determined by the increase in the absorbance at
405 nm. All experiments were performed in triplicate, with three
protein batches.
Assay for S-2238 hydrolysis
The hydrolysis of S-2238 (1 mM) by thrombin (1 nM) was mea-
sured in 20 mM Tris–HCl, 100 mM NaCl, pH 7.5, on a microplate
reader (Molecular Devices, Menlo Park, CA), after 5 min incubation
at 37 C, with varying suramin analog concentrations serially di-
luted. The reaction was initiated by the addition of S-2238, and
the initial rate of p-nitroaniline release was determined by follow-
ing the increase in absorbance at 405 nm. The original activity of
thrombin was calculated as the rate of S-2238 hydrolysis in the ab-
sence of ligands. All experiments were performed in triplicate, with
three protein batches.
Fluorescence polarization measurements
Fluorescence polarization measurements were performed in a
Spectramax M5 microplate reader (Molecular Devices), using ﬂuo-
rescein-D-Phe-Pro-Arg-chloromethyl ketone (F-PPACK) – labeled
thrombin (70 nM) in 20 mM Tris–HCl, 150 mM NaCl, pH 7.4,
25 C as previously described [6], by setting excitation to 490 nm
and measuring the ﬂuorescence emission at 520 nm. All measure-
ments were performed in triplicate.
Results
It has been previously shown that suramin (1b) exerts an inhib-
itory effect on the hydrolytic activity of thrombin toward both the
natural substrate ﬁbrinogen and the synthetic substrate S-2238
[18]. This effect is observed at moderate to high micromolar con-
centrations (Fig 2). Measurements performed at lower suraminconcentrations revealed another catalytic component resulting
from their interaction. Interestingly, at low micromolar concentra-
tion ranges and below, suramin led to a pronounced increase in
thrombin activity, followed by the inhibitory component (Fig 2).
Maximum activation occurred at 16 lM suramin, reaching approx-
imately 80% of activity enhancement (Table 1). The concentration
of suramin that produced half-maximal inhibition (IC50) was
approximately 65 lM, in accordance with the previous evaluation
[18].
To characterize the molecular origins of the activation proﬁle,
we have evaluated a number of suramin analogs bearing groups
of different polarity (e.g., alkyl, phenyl, halogen and methoxy sub-
stituents) in place of the methyl groups (1a–i; Table 1)’’. This
homologous series of large ureas (1a–i) showed similar behavior
as suramin (1b) itself, with an activation proﬁle at low concentra-
tions (7–30 lM), which lies within the same potency range (Fig. 3A
and B). They displayed maximum relative activities in the range of
20–50% enhancement, as shown in Table 1, except for the phenyl
(1e) and chlorine (1g) substituents, which exerted enhanced abili-
ties of thrombin activation against ﬁbrinogen, with relative maxi-
mum activities of 2.6 and 6.3 lM, respectively. The inhibitory
phase occurred at higher compound concentrations, with IC50 val-
ues in the range of 40–70 lM, except for the phenyl (1e) and chlo-
rine (1g) substituents, which have IC50 values of 129 and 197 lM,
respectively.
Fibrinogen interacts with thrombin through its active site and
exosite 1[24–26]. In contrast, suramin interacts with thrombin
through exosite 2, as shown by enzymatic [18] and crystallo-
graphic data[19]. Therefore, it is likely that the catalytic modula-
tion by suramin is an allosteric event mediated by the ligand
binding to exosite 2. To address this hypothesis, we evaluated
the effects of suramin and its analogs on the hydrolysis of the small
synthetic substrate S-2238 (Fig. 4), an active site-speciﬁc ligand, by
thrombin. As seen with ﬁbrinogen, the suramin analogs induced a
dual catalytic effect on thrombin activity over S-2238, supporting
the evidence for the allosteric nature of thrombin modulation by
suramin for both the activation and inhibition components (Fig. 4).
It is interesting to note that inhibitory effect of suramin towards
S-2238 cleavage is much less pronounced than the inhibition of the
ﬁbrinogen cleavage by thrombin. Suramin is a large symmetric
urea linking two polysulfonated naphthyl rings, comprising two
strongly anionic clusters. In our previous work, we have shown
by small-angle X-ray scattering and protein crystallography that
thrombin forms a dimer upon binding to suramin [19]. This dimer-
ization of thrombin occurs by the anchoring of two suramin mole-
cules, each one binding to both thrombin molecules. Therefore, we
Table 1
Activity of suramin analogs. Data were calculated from Fig 3.
Compound -R Concentration at
maximum activity (lM)
Maximum relative activity EC50 (lM) IC50 (lM)
1a (NF037) -H 16 1.43 ± 0.09 6 63
1b (Suramin) -CH3 20 1.82 ± 0.14 7 65
1c (NF127) -CH2CH3 16 1.16 ± 0.01 13 61
1d (NF151) -CH(CH3)2 16 1.33 ± 0.04 14 56
1e (NF198) -C6H5 32 2.53 ± 0.06 5 129
1f (NF157) -F 16 1.09 ± 0.06 13 36
1g (NF258) -Cl 16 6.32 ± 0.21 7 197
1h (NF260) -OCH3 8 1.44 ± 0.04 4 41
1i (NF222) -CH2OCH3 32 1.24 ± 0.09 21 60
2 (NF023) -H 32 1.40 + 0.05 21 180
3 (MK012) -H 32 2.11 + 0.02 13 182
Fig. 3. Effects of suramin analogs on thrombin catalytic activity over ﬁbrinogen.
Effects of increasing concentrations of suramin analogs over the activity of
thrombin (1 nM) against ﬁbrinogen (2 mg/mL) clotting. Ordinates are the relative
enzymatic activity, corresponding to the ratio between the initial rate of ﬁbrinogen
clotting in the presence/initial rate in its absence of the suramin analogs. Data
represent the mean ± S.D. of three independent determinations performed in
triplicate. (A) Compounds (1a) to (1e); (B) Compounds (1f) to (1i) and suramin (1b).
The enzymatic parameters obtained from these datasets, such as maximum activity
and IC50, are presented in Table 1.
Fig. 4. Effects of suramin analogs on the thrombin hydrolysis of the chromogenic
substrate S-2238. Effects of increasing concentrations of suramin analogs over the
activity of thrombin (1 nM) against S-2238 (1 mM). The ordinate is the relative
enzymatic activity, corresponding to the ratio between the initial rate of S-2238
hydrolysis in the presence/initial rate in its absence of suramin analogs (1a) to (1i),
(2) and (3), as stated in the ﬁgure. Data represent the mean ± S.D. of three
independent determinations performed in triplicate.
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ated by separated binding events: at ﬁrst, a 1:1 thrombin:suramin
complex resulting in the activation pattern, and thus a dimeriza-
tion event in the [thrombin:suramin]2 complex leading to the
inhibitory process.
To address this issue, we further tested smaller suramin analogs
with varying size and sulfonation degree, all of them with the
methyl group replaced by a hydrogen atom. Compound (3) is a
urea similar to compound (2), but with a phenyl-disulfonate in-
stead of a naphthalene trisulfonate. Reduction of the size and thus
the distance between the two naphthalene trisulfonate groups pro-
gressively led to an enhancement of activation potency at the cost
of the reduction of inhibition efﬁcacy (Fig. 5). This ﬁnding might be
due to the reduced ability of this shorter urea in promoting throm-
bin dimerization, while the activation element would rely mostly
on suramin binding to the thrombin exosite 2.
In order to gain further insights on the mechanisms of thrombin
activation and inhibition induced by suramin, we have assayed for
their interaction by ﬂuorescence polarization, using thrombin la-
beled with ﬂuorescein through the irreversible active-site inhibitor
D-Phe-Pro-Arg-chloromethyl ketone (PPACK). Fluorescence polari-
zation has long been used for the quantitative analysis of macro-
molecular association [27–30]. Free ﬂuorescein-labeled thrombin
showed a polarization value of about 0.14, which is compatible
with a monomeric form of thrombin (Fig. 6). Incubation of ﬂuores-
cein-thrombin with varying amounts of suramin up to 10 lM did
not result in changes in ﬂuorescence polarization. Further increase
of suramin concentration resulted in the progressive augment in
the ﬂuorescence polarization of ﬂuorescein-labeled thrombin from
0.14 to about 0.20, which can be attributed to an increase in its
hydrodynamic radii. The binding of a single suramin molecule toFig. 5. Minimal domains for thrombin activation. Suramin analogs were screened
for their activities over thrombin (1 nM) against ﬁbrinogen (2 mg/mL) clotting. The
ordinate is the relative enzymatic activity, corresponding to initial rate of ﬁbrinogen
clotting in the presence/initial rate in its absence of suramin analogs, as stated in
the ﬁgure. Data represent the mean ± S.D. of three independent determinations
performed in triplicate.
Fig. 6. Thrombin association induced by suramin probed by ﬂuorescence polari-
zation. Fluorescein-PPACK-thrombin (70 nM) was incubated with varying concen-
tration of suramin and the ﬂuorescence polarizarion was monitored. Data represent
the mean ± standard error of three independent determinations.
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rescence polarization due to its low molecular weight. Instead, we
attribute such phenomena to the association between thrombin
molecules, such as the formation of dimers of the complex [throm-
bin:suramin], in accordance with previous evidences obtained by
SAXS data [19].Discussion
The anion binding exosite 2 has long been seen as a target for
the design of sulfated allosteric inhibitors of thrombin [31–34].
Exosite 2 may interact with a number of ligands, including sulfated
compounds, such as the prothrombin activation fragment 2 (F2)
[35], ﬁbrin c0 peptide (sulfated at tyrosine; ﬁbrin itself interacts
with exosite I) and platelet glycoprotein Ib [36,37], which is one
of the four proteins in the GPIb-IX-V platelet receptor complex.
GPIb is sulfated at tyrosine residues 276, 278 and 279, which
are known for their interaction with thrombin at exosite 2 [38]
at the same interaction site as the sulfonated naphthyl group of
suramin [19]. The crystal structure of thrombin in complex with
the ﬁbrin c0 peptide (PDB ID 2HWL) reveals a dimer in the asym-
metric unit (as modeled from crystal symmetry) that is maintained
by the cross interaction of one ﬁbrin c0 peptide with the exosite 2
from two distinct thrombin monomers [39]. The sulfated Tyr422 of
the ﬁbrin c0 peptide interacts at the same epitope of thrombin that
is responsible for heparin recognition [39], which is also the site of
interaction for the sulfonated moiety of suramin.
These cofactors that recognize the allosteric procoagulant activ-
ities that exosite 2 exerts over thrombin have a common feature,
which is that they have at least one sulfated amino acid at the pro-
tein domain which is responsible for the recognition and binding to
thrombin. For suramin, we have found two opposing behaviors in
its interaction with thrombin: the activation and inhibition of cat-
alytic activity. Previous calorimetric evidences have also suggested
two molecular events in the interaction of thrombin with suramin
[18], which has been corroborated by crystal and solution struc-
tural studies [19]. However, the molecular binding mechanism be-
tween thrombin and suramin and its consequence on the behavior
of single-phased enzyme activity was not exactly clear.
In this study, we have shown that submicromolar concentra-
tions of suramin and suramin anaolgues, below the concentration
previously investigated, were sufﬁcient to increase thrombin enzy-
matic activities toward both natural and synthetic substrates. In
fact, only part of the symmetric suramin molecule seems to exert
the activation effect over thrombin, as it was observed that
decreasing the urea size progressively increases its activationefﬁcacy over thrombin activity (Fig. 5). Moreover, the large urea
series varies only at the methyl group position. However, the chlo-
rine (1e) and phenyl (1g) substituted suramin analogs displayed
higher activations compared to the other compounds in this series.
These data suggest that the molecular volume of the substituents
may play an important role on the allosteric regulation of throm-
bin. Such substituents are likely to occupy a cavity in the thrombin
delimited by side chains from Gln256 Trp237, Tyr89, and Val241
(Fig. 1C), creating a peculiar, mixed environment.
At present, our data indicate that part of the suramin molecule
delimited by the region comprised between the methyl-substi-
tuted ring and the disulfonated aromatic ring moiety comprise a
minimal ligand motif for thrombin activation through exosite 2.
Moreover, in conjunction with the previous crystal structure of
thrombin in complex with heparin, which reveals an oligomer in
the asymmetric unit [40] through exosite 2, these data indicate
that thrombin dimerization can be mediated by exosite 2 cofactors,
leading to potential inhibitory effects over thrombin. These data al-
low us to raise the hypothesis for a cofactor-mediated, oligomeri-
zation-driven mechanism for the reduction of clotting rate.
In the present study we have evaluated the effect of suramin
over the enzymatic activity of thrombin against two dissimilar
substrates, the small chromogenic peptide S-2238 and the natural
ligand ﬁbrinogen. We have observed that suramin exerts a more
pronounced inhibitory effect over ﬁbrinogen cleavage by thrombin
compared to the cleavage of the short S-2238 molecule. While S-
2238 interaction with thrombin relies in contacts established be-
tween the ligand and the active cleft of the enzyme, ﬁbrinogen
cleavage by thrombin requires contacts at both the active site
and the anion binding exosite 1. In fact, the ability of ligands to
exosites 1 and 2 in promoting allosteric changes on the catalytic
site of thrombin has been well documented, and several evidences
suggest a long range allosteric linkage between exosites 1 and 2
[41–43]. Thus, exosite 2 ligands would induce allosteric change
in thrombin resulting in altered afﬁnity of ligands to exosite 1,
which could be related to the ability of suramin in altering the efﬁ-
cacy of thrombin in promoting ﬁbrinogen clotting.
The two anion binding exosites in thrombin are important for
substrate and/or cofactor binding and regulation. It has been sug-
gested that the binding features of exosite 1 contain an extensive
contribution from the hydrophobic component, while the cofactor
binding to exosite 2 is largely driven by electrostatic forces[44]. In
fact, it is likely that the interaction of suramin and suramin analogs
with exosite 2 is highly favorable by the electrostatic contributions
of their sulfonated groups and basic residues from thrombin [19]. It
is even more likely that most natural cofactors of exosite 2 are sul-
fated compounds.
Collectively, these data shed light on a distinguished feature of
exosite 2 that exerts a key role in thrombin regulation as a proco-
agulant allosteric site in the immediate beginning of the clotting
event in the blood coagulation cascade through the binding of sul-
fated cofactors. Additionally, it is highly desirable to develop
procoagulants (small-molecule compounds targeting coagulation
enzymes such as thrombin) as a therapeutic strategy to control
bleeding and manage blood loss in clinical situations, such as dur-
ing surgical procedures. This strategy can be implemented to avoid
antibody-mediated coagulopathy against bovine thrombin or
immunogenic contaminants in recombinant human thrombin,
which are the current therapeutic strategies.
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